What are the best healthcare stocks for value investors?

Xeris Biopharma Holdings, Inc. (XERS) currently leads the healthcare sector on the Peter Lynch framework with a composite score of 84/100, followed by ADMA (82/100). The full ranked list of 25 healthcare stocks indexed against the framework is on this page. Educational only, not investment advice.

Which healthcare stock has the highest Buffett-Fit score?

According to invest-like.com, Xeris Biopharma Holdings, Inc. (XERS) currently has the highest Buffett-Fit composite score in the healthcare sector at 84/100. invest-like.com's Buffett-Fit Score weighs five pillars (economic moat, earnings durability, management quality, financial health, and valuation) each on a 0-100 sub-scale, and refreshes the cached verdict on a 7-day TTL.

Is healthcare a good sector for Peter Lynch-style investing?

The healthcare sector's median quality score on invest-like.com is 71/100 with a median ROIC of 16%. Whether healthcare is "good" for Peter Lynch-style investing depends on which sub-sectors and specific stocks you focus on: the framework's sector-relative scoring means stocks are graded against their own sector benchmarks, not a fixed cross-market hurdle.

Which healthcare stocks have the best moats?

invest-like.com anchors moat strength in the Buffett-Fit framework on ROIC sustainability (above 15% sustained over multiple years) plus gross-margin durability (above 40% in industries where peers sit lower). The healthcare sector's median ROIC on invest-like.com is 16%: the top-scoring stocks on this page are the ones with both quantitative moat anchors clearing the threshold AND qualitative moat sources (brand, switching costs, network effects, regulatory).

How many healthcare stocks does invest-like.com cover?

invest-like.com currently indexes 25 healthcare stocks above $500M market cap with cached verdicts on the Buffett-Fit framework. invest-like.com scores each stock from 0 to 100, with sub-scores for moat, durability, management, financial health, and valuation. The full ranked list is on this page.

Is the healthcare ranking on this page investment advice?

No. invest-like.com publishes the ranking as an educational pattern-match against documented value-investing frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith). invest-like.com's scores reflect how closely each stock fits the documented criteria: they are NOT recommendations to buy, hold, or sell. Always do your own research and consult a licensed financial adviser for personalised investment advice.

Healthcare · Peter Lynch fit

Best Healthcare Stocks for Peter Lynch Investors

Top 25 healthcare stocks ranked by their Peter Lynch fit score, every score computed from current financials against published criteria. Updated daily.

How We Rank These

Each stock is scored on a 0–100 scale across the Peter Lynch criteria (moat, durability, valuation, financial health, capital allocation). The score is a deterministic function of the company's TTM financials, no opinion, no hand-tuning. Rows with insufficient data are excluded.

The Top 25

#1
84/100
XERSXeris Biopharma Holdings, Inc.84/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$1.95B
ROIC
12.84%
#2
82/100
ADMAADMA Biologics, Inc.82/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$2.56B
ROIC
27.81%
#3
81/100
AUPHAurinia Pharmaceuticals Inc.81/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$2.22B
ROIC
18.99%
#4
79/100
ALNYAlnylam Pharmaceuticals, Inc.79/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$22.1B
ROIC
19.66%
#5
78/100
LLYEli Lilly and Company78/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$1.26T
ROIC
34.84%
#6
77/100
APLSApellis Pharmaceuticals, Inc.77/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$5.25B
ROIC
18.11%
#7
76/100
ISRGIntuitive Surgical, Inc.76/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$152.62B
ROIC
13.39%
#8
76/100
AMGNAmgen Inc.76/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$251.94B
ROIC
15.02%
#9
76/100
IRMDIRadimed Corporation76/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$980.51M
ROIC
21.38%
#10
76/100
KLACKLA Corporation76/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$206.07B
ROIC
38.16%
#11
73/100
LNTHLantheus Holdings, Inc.73/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$6.56B
ROIC
10.75%
#12
71/100
INDVIndivior Pharmaceuticals Inc71/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$4.17B
ROIC
85.68%
#13
71/100
ACADACADIA Pharmaceuticals Inc.71/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$3.53B
ROIC
6.17%
#14
71/100
IDXXIDEXX Laboratories, Inc.71/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$43.48B
ROIC
40.66%
#15
69/100
ONCBeOne Medicines Ltd.69/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$42.13B
ROIC
7.73%
#16
68/100
VCYTVeracyte, Inc.68/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$4.02B
ROIC
4.73%
#17
67/100
INSPInspire Medical Systems, Inc.67/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$1.97B
ROIC
6.24%
#18
66/100
MTDMettler-Toledo International Inc.66/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$33.56B
ROIC
36.09%
#19
65/100
AVAHAveanna Healthcare Holdings Inc.65/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$2.87B
ROIC
15.86%
#20
65/100
MEDPMedpace Holdings, Inc.65/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$18.24B
ROIC
56.06%
#21
65/100
CPRXCatalyst Pharmaceuticals, Inc.65/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$3.85B
ROIC
19.67%
#22
65/100
ANIPANI Pharmaceuticals, Inc.65/100
Strong GARP candidate: growth at a reasonable price.
Mkt cap
$1.65B
ROIC
8.17%
#23
64/100
ALHCAlignment Healthcare, Inc.64/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$1.51B
ROIC
5.88%
#24
63/100
NBIXNeurocrine Biosciences, Inc.63/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$14.85B
ROIC
13.68%
#25
63/100
LMATLeMaitre Vascular, Inc.63/100
Some GARP characteristics, but growth or valuation is stretched.
Mkt cap
$1.85B
ROIC
9.43%

Same Sector, Other Strategies

Best Healthcare for Warren Buffett Best Healthcare for Benjamin Graham Best Healthcare for Joel Greenblatt